Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132373 | 0.81 | ADORA3 (0.47) | ALDH1A1RXFP1KMT2AMEN1MAPT | |
| SCHEMBL4132401 | 0.80 | ADORA3 (0.43) | ALDH1A1MAPTKDM4ELMNANPC1 | |
| SCHEMBL4132353 | 0.80 | PIK3C3 (0.40) | ALDH1A1MAPTKDM4ENPC1POLB | |
| SCHEMBL4144446 | 0.74 | ADORA3 (0.48) | NTRK1ALDH1A1RXFP1KMT2AMEN1 | |
| SCHEMBL4144040 | 0.73 | LMNA (0.54) | NTRK1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL23331258 | 0.71 | PTK2 (0.43) | ALDH1A1KMT2AMEN1KDM4EPOLB | |
| SCHEMBL11375967 | 0.69 | KMT2A (0.42) | NTRK1ALDH1A1RXFP1KMT2AMEN1 | |
| SCHEMBL16586810 | 0.68 | NTRK1 (1.00) | NTRK1RXFP1MAPTPOLBTHRB | |
| SCHEMBL16824917 | 0.68 | RXFP1 (0.55) | ALDH1A1RXFP1KMT2AMEN1MAPT | |
| SCHEMBL17773665 | 0.67 | MEN1 (0.51) | ALDH1A1KMT2AMEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005560-A1 | PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS | AJINOMOTO CO. INC (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-2009003-A1 | Production method of diaminopyrimidine compounds | Ajinomoto Co., Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005560-A1 | PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS | DPYD, DHPS, UMPS | NTRK1 4475/4885ALDH1A1 165/4885RXFP1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.